CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma

Zhou, Yüxia; Li, Cheng; Wang, Zhenping; Tan, Shuangfeng; Liu, Yiqi; Zhang, Hu; Li, Xuefeng

doi:10.3389/fmolb.2022.833079

Cited by 6 publications

(1 citation statement)

References 155 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal cell carcinoma (RCC) is one of the most lethal of human disease, accounting for 2-3% of adult malignancies in the world, while clear-cell renal cell carcinoma accounts for approximately 80% of RCC [1,2] . The early diagnosis and complete surgical excision are the main factors contributing to a de nitive treatment of ccRCC.…”

Section: Introductionmentioning

confidence: 99%

BAP1 serves as a clear-cell renal cell carcinoma suppressor and is inversely regulated by miR-200c-3p

Wei,

Wenyu,

Ling

et al. 2024

Preprint

View full text Add to dashboard Cite

The initiation and development of malignant tumor is always accompanied by a series of complex gene expression alterations inside the cells. As a tumor suppressor, the deubiquitinating enzyme BAP1 has been identified as an important regulator on the outcomes and biological properties of clear-cell renal cell carcinoma (ccRCC). However, BAP1-involved intracellular regulatory cascades in clear-cell renal cell carcinoma are still not fully understood. In this study, we provided evidence that the protein levels of BAP1 were dramatically diminished in clear-cell renal cell carcinoma in vitro and in vivo. Notably, the relatively low expression of BAP1 is significantly associated with worse prognosis in ccRCC patients. Besides, through the prediction of bioinformatics methods and verification of biological experiments, we confirmed that miR-200c-3p was the direct upstream regulator of BAP1. Taken together, our study presents an important role of miR-200c-3p/BAP1 in the development of ccRCC, which provided an alternative strategy for treating ccRCC in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

BAP1 serves as a clear-cell renal cell carcinoma suppressor and is inversely regulated by miR-200c-3p

Wei,

Wenyu,

Ling

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Integrative analysis of bulk and single‐cell RNA sequencing reveals sphingolipid metabolism and immune landscape in clear cell renal cell carcinoma

Xie,

Han,

Wang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is characterized by its aggressive behavior and complex molecular heterogeneity, posing significant challenges for treatment and prognostication. This study offers a comprehensive analysis of ccRCC by leveraging both bulk and single‐cell RNA sequencing data, with a specific aim to unravel the complexities of sphingolipid metabolism and the intricate dynamics within the tumor microenvironment (TME). By examining ccRCC samples sourced from public databases, our investigation delves deep into the genetic and transcriptomic landscape of this cancer type. Employing advanced analytical techniques, we have identified pivotal patterns in gene expression and cellular heterogeneity, with a special focus on the roles and interactions of various immune cells within the TME. Significantly, our research has unearthed insights into the dynamics of sphingolipid metabolism in ccRCC, shedding light on its potential implications for tumor progression and strategies for immune evasion. A novel aspect of this study is the development of a risk score model designed to enhance prognostic predictions for ccRCC patients, which is currently pending external validation to ascertain its clinical utility. Despite its contributions, the study is mindful of its limitations, including a reliance on observational data from public sources and a primary focus on RNA sequencing data, which may constrain the depth and generalizability of the findings. The study does not encompass critical aspects, such as protein expression, posttranslational modifications, and comprehensive metabolic profiles. Moreover, its retrospective design underscores the necessity for future prospective studies to solidify these preliminary conclusions. Our findings illuminate the intricate interplay between genetic alterations, sphingolipid metabolism, and immune responses in ccRCC. This research not only enhances our understanding of the molecular foundations of ccRCC but also paves the way for the development of targeted therapies and personalized treatment modalities. The study underlines the importance of cautious interpretation of results and champions ongoing research using diverse methodologies to thoroughly comprehend and effectively combat this formidable cancer type.

show abstract

CircJag1 promotes apoptosis of ethylene thiourea–exposed anorectal malformations through sponging miR-137-3p by regulating Sox9 and suppressing Wnt/β-catenin pathway during the hindgut development of rat embryos

Wang

Wei

et al. 2022

Cell Biol Toxicol

View full text Add to dashboard Cite

CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma

Cited by 6 publications

References 155 publications

BAP1 serves as a clear-cell renal cell carcinoma suppressor and is inversely regulated by miR-200c-3p

BAP1 serves as a clear-cell renal cell carcinoma suppressor and is inversely regulated by miR-200c-3p

Integrative analysis of bulk and single‐cell RNA sequencing reveals sphingolipid metabolism and immune landscape in clear cell renal cell carcinoma

CircJag1 promotes apoptosis of ethylene thiourea–exposed anorectal malformations through sponging miR-137-3p by regulating Sox9 and suppressing Wnt/β-catenin pathway during the hindgut development of rat embryos

Contact Info

Product

Resources

About